PhaseBio Pharmaceuticals — Investor Presentation (March 2020)
28 slides from PhaseBio Pharmaceuticals's investor presentation, Mar 30, 2020
Slide 1: Corporate Overview March 2020
Corporate Overview March 2020
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”)
Slide 3: Company Overview
Company Overview Therapeutic Focus Clinical-stage biopharma company focused on the development and commercialization of novel therapies to treat cardiopulmonary indications PB2452 – Novel agent for immediate and sustained reversal of ticagrelor, the preferred antiplatelet therapy of the American Col
Slide 4: A Clinical Stage, Cardiopulmonary Focused Biopharmaceutical Company
A Clinical Stage, Cardiopulmonary Focused Biopharmaceutical Company Program Indication/Therapeutic Area Pre-Clinical Phase 1 Phase 2 Phase 3 WW Commercial Rights Milestones Q1 2020: • Initiated Phase 3 trial Reversal of Ticagrelor Phase 3 ongoing PB2452 based on plan to pursue Breakthrough Therapy d
Slide 5: Corporate
Corporate
Slide 6: Creating Value for Stakeholders in 2020
Creating Value for Stakeholders in 2020 • Following a successful 2019, PhaseBio continues a rapid pace of development and execution in 2020 Announced innovative funding and co-development collaboration for PB2452 with SFJ Pharmaceuticals Bolstered pipeline with acquisition of resistant hypertens
Slide 7: Fourth-Quarter 2019 Financial Highlights
Fourth-Quarter 2019 Financial Highlights • Operating expense: $12.0M − R&D: $8.4M − SG&A: $3.7M • Loss from Operations: ($11.3M) • Net Loss of ($11.3M) or ($0.39) per share − 28.8M shares used for computing Q4 2019 net loss per share • Cash and cash equivalents as of 12/31/2019: $74.0M All values in
Slide 8: Experienced Management Team
Experienced Management Team JONATHAN MOW Amylin Pharmaceuticals, Corus Pharma, Chief Executive Officer PathoGenesis, BMS SUSAN ARNOLD, PhD Targeted Genetics, Viromed Biosafety Labs, VP of Preclinical & CMC BioRexis, NuPathe JIM BALLANCE, PhD Delta Biotechnology, Aventis Behring, BioRexis VP Research
Slide 9: PB2452 – Reversal Agent for Ticagrelor
PB2452 – Reversal Agent for Ticagrelor
Slide 10: PB2452 - Novel reversal agent for Brilinta (ticagrelor)
PB2452 - Novel reversal agent for Brilinta (ticagrelor) • Within the P2Y12 antagonist class of oral antiplatelet therapies, ticagrelor has proven superiority vs. clopidogrel, and a unique reversible binding profile − Clopidogrel and prasugrel, the other members of the oral P2Y12 antagonist class, bo
Slide 11: PB2452: Well-Characterized Mechanism of Reversal of Ticagrelor
PB2452: Well-Characterized Mechanism of Reversal of Ticagrelor Ticagrelor PB2452 ADP This is a reversible ADP ADP process with P2Y12 ticagrelor cycling Platelet Receptor on/off the P2Y12 receptors ADP binds to P2Y12 receptor Ticagrelor binds to P2Y12, inhibiting PB2452 binds to free ticagrelor 1. ca
Slide 12: PB2452: Development and Regulatory Timelines
Clinical Studies PB2452: Development and Regulatory Timelines BLA enabling data 2019 2020 2021 2022 2023 NEJM Phase 2a Phase 2b: Older and elderly subjects N=200, 150 randomized to receive PB2452 Breakthrough FDA Therapy EOP1 Phase 3 Interim Analysis for Accelerated Approval Post-approval completion
Slide 13: PB2452 Phase 1 Proof-of-Concept Study in Healthy Subjects
PB2452 Phase 1 Proof-of-Concept Study in Healthy Subjects • Randomized, double-blind, placebo-controlled, single ascending dose (SAD), sequential group study (n=64) • Platelet function evaluated using three well established and commonly used assays: LTA, VerifyNow PRUTest® and VASP − Results from al
Slide 14: Normalized Platelet Function After Ticagrelor Reversal
Normalized Platelet Function After Ticagrelor Reversal VerifyNow PRUTest Normal Platelet Inhibited Platelet Return to Normal Function: Pre- Function: Post- Platelet Function: Ticagrelor Dosing Ticagrelor Dosing Post-PB2452 Dosing Normal Platelet Function Inhibited Platelet Function PRU= Platelet Rea
Slide 15: Positive Preliminary PB2452 Phase 2a Results
Positive Preliminary PB2452 Phase 2a Results • Positive preliminary results from the PB2452 Phase 2a trial were disclosed via press release1 − First trial of PB2452 to include older and elderly subjects (ages 50-80) on dual antiplatelet therapy (DAPT) of ticagrelor and low-dose aspirin − Subjects in
Slide 16: PB2452 Regulatory Updates
PB2452 Regulatory Updates Development plan for PB2452 designed with objective to broadly support global regulatory filings Separate written guidance from FDA and EMA indicates that a single, non-randomized, open-label Phase 3 trial of PB2452 in both surgical and major bleeding populations has the po
Slide 17: PB2452 Pivotal Phase 3 Trial Overview
PB2452 Pivotal Phase 3 Trial Overview • Phase 3 trial is a key element of development plan that has garnered FDA Breakthrough Therapy and EMA PRIME designations • Open-label, single-arm study of reversal of the antiplatelet effects of ticagrelor with PB2452 in patients who present with uncontrolled
Slide 18: SFJ Pharmaceuticals Funding and Co-Development Collaboration
SFJ Pharmaceuticals Funding and Co-Development Collaboration • Innovative collaboration between SFJ and PhaseBio to support the global development of PB2452 • SFJ will fund up to $120 million to support the clinical development of PB2452 − SFJ has extensive experience in the global clinical developm
Slide 19: Expect Continued Long-Term Rx Growth of Ticagrelor
Expect Continued Long-Term Rx Growth of Ticagrelor PB2452 approval has the potential to drive continued positive momentum • Brilinta/Brilique sales in 2019 were $1.58B and growing (+20% Y/Y) − Patient growth drives Y/Y revenue growth in key regions: strong growth in the United States and Emerging Ma
Slide 20: PB1046 - Once Weekly VIP Analog for Pulmonary Arterial Hypertension
PB1046 - Once Weekly Vasoactive Intestinal Peptide (VIP) Analog for Pulmonary Arterial Hypertension
Slide 21: High Unmet Need in an Orphan Disease
High Unmet Need in an Orphan Disease Primary Pulmonary Arterial Hypertension (PAH, WHO Group 1 PH) McGlaughlin et al. (2015) J. Am. Coll. Cardiol., 65:18 • High unmet need for novel disease-modifying PAH therapies for greater efficacy − All 3 approved drug classes in PAH are vasodilators: prostacycl
Slide 22: PB1046: Harnessing VIP to Create a Stable, Long-Acting Drug
PB1046: Harnessing VIP to Create a Stable, Long-Acting Drug VIP as a THERAPEUTIC AGENT VPAC2 VPAC2 VPAC1 VPAC1 VIP Peptide PB1046 Half-Life ~ 1 minute in Humans Half-Life ~60 Hours in Humans PRECLINICAL STUDIES MECHANISM OF ACTION VIA VPAC2 RECEPTOR Support Clinical Development for: • Potent vasodil
Slide 23: Proprietary Elastin-Like Polypeptide (ELP) Technology
Proprietary Elastin-Like Polypeptide (ELP) Technology Key to optimizing the profile of an injectable VIP product candidate PROLONGED CIRCULATING HALF-LIFE COACERVATION DELIVERS SLOW RELEASE “Biopolymer” Outside Body Inside Body Repeating ↑ Active Moiety Sequence of Temperature Human Elastin Peptides
Slide 24: PB1046 Clinical Development Activities to Date
PB1046 Clinical Development Activities to Date Have Supported Advancement into a Phase 2b PAH Efficacy Study PHASE 1 Studies Completed PAH PHASE 2 Studies SAD study in HTN 4-week MAD study Open-Label Phase 2a Phase 2b PAH Efficacy patients washed in HFrEF patients CardioMEMS in PAH study: Safety 16-
Slide 25: PB6440 – Aldosterone Synthase Inhibitor for Resistant Hypertension
PB6440 – Aldosterone Synthase Inhibitor for Resistant Hypertension
Slide 26: PB6440 for Resistant Hypertension
PB6440 for Resistant Hypertension • Upwards of 10 million patients in the United States have resistant hypertension and are at risk for serious, costly medical consequences (stroke, heart attack, kidney failure, etc.)1 • Physicians currently prescribe numerous combinations of antihypertensives to lo
Slide 27: PB6440 is Highly Selective for Aldosterone Synthase (CYP11B2)
PB6440 is Highly Selective for Aldosterone Synthase (CYP11B2) Selectivity and Potency Demonstrated in Primate Chronic Oral Dosing Model CYP11B Potency and Selectivity (IC50, µM) Human Monkey CYP11B2 CYP11B1# Selectivity CYP11B2 CYP11B1 Selectivity PB6440 PB6440 PB6440 0.024 4.859 202 0.016 5.802 363
Slide 28: Slide 28
PhaseBio Pharmaceuticals — Investor Presentation (March 2020) on 6ix